Stock listing

gettex:IDD Innate Pharma SA Aktie

German listing (gettex) of Innate Pharma SA · home listing Euronext:IPH

Follow Innate Pharma SA into a list and get an email when it puts out news.

Home listing price · EURONEXT:IPH

€1.30 EUR +0.01 (+0.6%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, EURONEXT:IPH

Innate Pharma SA logo
Ticker
gettex:IDD
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
gettex
Currency
EUR

What changed lately

Calls

Replays

  • Innate Pharma (Euronext:IPH) Q1 2026 Earnings Call

    Wed, May 13, 2026 · 7:30 AM ET

    Watch Transcript

  • Innate Pharma (Euronext:IPH) Q4 2025 Earnings Call

    Thu, Mar 26, 2026 · 9:00 AM ET

    Watch Transcript

  • Innate Pharma (Euronext:IPH) Q3 2025 Earnings Call

    Thu, Nov 13, 2025 · 8:00 AM ET

    Watch Transcript

Latest news

Innate Pharma Reports First Half 2026 Business Update and Financial Results

Sep 17, 2026

Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions

Sep 16, 2026

Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update

Sep 10, 2026

Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Sep 2, 2026

Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares

Aug 14, 2026

Innate Pharma Announces Proposed Offering of Ordinary Shares

Aug 13, 2026

Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

Aug 10, 2026

Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

Aug 10, 2026

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

Jul 23, 2026

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

Jul 21, 2026

All Innate Pharma SA news

Financings

  • Private placement of new ordinary shares

    Aug 14, 2026 · US$34.72M

    Update: about €30M · €1.7 a share · Stifel +1

    Dealers: Stifel (lead), BTIG (co-lead)

    Buyers: Bpifrance Participations S.A. (committed to place a €3 million order in the book)

    Use of proceeds: Clinical development of IPH4502, advancing preclinical ADC portfolio candidates, working capital and general corporate purposes

    Announced Aug 13, 2026 · Update Aug 14, 2026

Read by 6ix AI from the company's releases

Decks

Innate Pharma SA on 6ix

Sector
Health care
Industry
Biotechnology
News releases
34 in the last 12 months · 54 in all · newest Sep 17, 2026 · oldest 2025
Calls
15 calls with a replay · 15 with a transcript · latest May 13, 2026
Decks
76 decks · latest August 2026

Where Innate Pharma SA is listed

ListingExchangeCountryCurrency
Euronext:IPH · Home listingEuronextFranceEUR
NASDAQ:IPHANASDAQUnited StatesUSD
gettex:IDD · This pagegettexGermanyEUR
EUROTLX:4IPHEUROTLXItalyEUR
OTC:IPHYFOTCUnited StatesUSD
LSIN:0EVILSINUnited KingdomEUR
LS Exchange:A0LCUJLS ExchangeGermanyEUR
Aquis:IPHPAquisUnited KingdomEUR
Lang & Schwarz:A0LCUJLang & SchwarzGermanyEUR
Aquis:IPHPAquisUnited KingdomEUR
Stuttgart:IDDStuttgartGermanyEUR
Xetra:IDDXetraGermanyEUR
Tradegate:IDDTradegateGermanyEUR
Frankfurt:IDDAFrankfurtGermanyEUR
BOATS:IPHABOATSUnited StatesUSD
gettex:IDDAgettexGermanyEUR
Frankfurt:IDDFrankfurtGermanyEUR
Dusseldorf:IDDDusseldorfGermanyEUR
Hamburg:IDDHamburgGermanyEUR
Lang & Schwarz:A2PSSHLang & SchwarzGermanyEUR
Munich:IDDMunichGermanyEUR
Munich:IDDAMunichGermanyEUR
LS Exchange:A2PSSHLS ExchangeGermanyEUR
Stuttgart:IDDAStuttgartGermanyEUR
Turquoise:IPHPTurquoiseUnited KingdomEUR
Hanover:IDDHanoverGermanyEUR

Log in to ask 6ix AI your own questions about Innate Pharma SA.